WASHINGTON, Feb. 10, 2022 /PRNewswire/ -- Healis
Therapeutics, a privately held biotechnology company, today
announces its ownership of a key botulinum toxin patent from AbbVie
(NYSE: ABBV).
After clinically significant results in early trials, Allergan
acquired the rights to develop botulinum toxin for depression in
2013. Allergan completed a Phase II study in 2017 and announced
plans for Phase III. AbbVie assumed ownership through its 2020
acquisition of Allergan.
Today, Healis Therapeutics takes over the exclusive license from
AbbVie to develop botulinum toxin as a potential treatment for
Major Depressive Disorder (MDD).
As of February 2022, botulinum
toxin for depression has passed through eight successful Phase II
clinical trials.
Ownership of the exclusive license is expected to accelerate
Healis' mission to develop BT for depression.
Disclaimer: As of 10 February
2022, botulinum toxin is not an FDA approved drug for the
treatment of major depressive disorder (MDD). Botulinum toxin for
MDD is under investigational use only and not available for
commercial distribution.
Inquiry:
info@healisthera.com
808 726 1720
View original content to download
multimedia:https://www.prnewswire.com/news-releases/healis-therapeutics-acquires-ownership-of-key-botulinum-toxin-patent-301479416.html
SOURCE Healis Therapeutics